Literature DB >> 10952638

Idiopathic thrombocytopenic purpura.

P H Bolton-Maggs1.   

Abstract

Idiopathic thrombocytopenic purpura in children usually a self limiting disorder. It may follow a viral infection or immunisation and is caused by an inappropriate response of the immune system. About 20-30% of children will fail to remit over six months (chronic idiopathic thrombocytopenic purpura). This is more likely in older children, especially girls. The disease is reviewed with reference to diagnosis, investigation, and management options.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952638      PMCID： PMC1718449          DOI： 10.1136/adc.83.3.220

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  24 in total

1.  Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.

Authors:  I Warrier; J B Bussel; L Valdez; J Barbosa; D S Beardsley
Journal:  J Pediatr Hematol Oncol       Date:  1997 May-Jun       Impact factor: 1.289

2.  The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies.

Authors:  Y Najean; J D Rain; C Billotey
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

Review 3.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.

Authors:  J N George; S H Woolf; G E Raskob; J S Wasser; L M Aledort; P J Ballem; V S Blanchette; J B Bussel; D B Cines; J G Kelton; A E Lichtin; R McMillan; J A Okerbloom; D H Regan; I Warrier
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

4.  Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis.

Authors:  M J Manco-Johnson; R Nuss; N Key; C Moertel; L Jacobson; S Meech; A Weinberg; J Lefkowitz
Journal:  J Pediatr       Date:  1996-03       Impact factor: 4.406

5.  Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.

Authors:  V Blanchette; P Imbach; M Andrew; M Adams; J McMillan; E Wang; R Milner; K Ali; D Barnard; M Bernstein
Journal:  Lancet       Date:  1994-09-10       Impact factor: 79.321

6.  Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome.

Authors:  M M Reid
Journal:  Arch Dis Child       Date:  1995-02       Impact factor: 3.791

Review 7.  Leukemia in Down syndrome: a review.

Authors:  A Zipursky; A Poon; J Doyle
Journal:  Pediatr Hematol Oncol       Date:  1992 Apr-Jun       Impact factor: 1.969

Review 8.  Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology.

Authors:  J S Lilleyman
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

9.  Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura.

Authors:  J W Taub; I Warrier; C Holtkamp; D S Beardsley; J M Lusher
Journal:  Am J Hematol       Date:  1995-02       Impact factor: 10.047

10.  Chronic childhood idiopathic thrombocytopenia purpura: long-term follow-up.

Authors:  H Tamary; C Kaplinsky; I Levy; I J Cohen; I Yaniv; B Stark; Y Goshen; R Zaizov
Journal:  Acta Paediatr       Date:  1994-09       Impact factor: 2.299
View more
  8 in total

1.  MMR vaccine and idiopathic thrombocytopaenic purpura.

Authors:  Corri Black; James A Kaye; Hershel Jick
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 2.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

Review 3.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

4.  Determining a definite diagnosis of primary immune thrombocytopenia by medical record review.

Authors:  Deirdra R Terrell; Laura A Beebe; Sara K Vesely; Barbara R Neas; Jodi B Segal; James N George
Journal:  Am J Hematol       Date:  2012-06-20       Impact factor: 10.047

5.  Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study.

Authors:  Masaru Kubota; Souichi Adachi; Ikuya Usami; Masayuki Okada; Toshiyuki Kitoh; Mitsutaka Shiota; Yoshihiro Taniguchi; Akihiko Tanizawa; Mitsuhiko Nanbu; Keigo Hamahata; Hisanori Fujino; Kousaku Matsubara; Yoshihiro Wakazono; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

6.  Immune Thrombocytopenic Purpura in Children and Adults: A Comparative Retrospective Study in IRAN.

Authors:  Sajedeh Saeidi; Kaveh Jaseb; Ali Amin Asnafi; Fakher Rahim; Fatemeh Pourmotahari; Samira Mardaniyan; Homayon Yousefi; Arash Alghasi; Mohammad Shahjahani; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014-07-01

7.  Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia.

Authors:  Gabriel Tremblay; Mike Dolph; Menaka Bhor; Qayyim Said; Anuja Roy; Brian Elliott; Andrew Briggs
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-05

8.  High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up.

Authors:  Chae Young Kim; Eun Hye Lee; Hoi Soo Yoon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.